Company intelligence / Profile preview

Yoshino Neurology Clinic

Ichikawa, Chiba, Japanyoshino-clinic.jp ↗

Ownership: Private
Development stage: Commercial

Overview

The clinic provides treatment for neurological conditions, with a particular focus on Edaravone treatment for ALS patients. Edaravone can slow disease progression by approximately 30-40% compared to placebo for early-stage ALS patients[3].

Therapeutic areas: Neurology
Modalities: Pharmaceuticals (Edaravone, Riluzole, Rilutek, Ketas/Ibudilast)
Industry: Non-Academic Healthcare

Drug pipeline

1 asset

fruquintinib

Commercial

Indications: Colorectal cancer, Metastatic colorectal cancer

Beyond the preview

Go deeper on Yoshino Neurology Clinic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yoshino Neurology Clinic.

Explore the full profile